Beneficial impact of xuezhikang on cardiovascular events and mortality in elderly hypertensive patients with previous myocardial infarction from the China coronary secondary prevention study (CCSPS)

Journal of Clinical Pharmacology

Volumn 49, Issue 8, 2009, Pages 947-956

  Li, Jian Jun ^a   Lu, Zong Liang ^a   Kou, Wen Rong ^a   Zuo Chen, ^a   Wu, Yang Feng ^a   Yu, Xue Hai ^a   Zhao, Yu Cheng ^a  

^a FUWAI HOSPITAL   (China)

Author keywords

Cardiovascular event; Elderly; Hypertension; Myocardial infarction; Statin; Xuezhikang

Indexed keywords

ACETYLSALICYLIC ACID; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; NITRATE; PLACEBO; XUEZHIKANG;

AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; CHINESE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATINE KINASE BLOOD LEVEL; CREATININE BLOOD LEVEL; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG SAFETY; EDEMA; ERECTILE DYSFUNCTION; FEMALE; GASTROINTESTINAL SYMPTOM; HEART INFARCTION; HUMAN; HYPERTENSION; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; MORTALITY; MULTICENTER STUDY; MYALGIA; MYOPATHY; NEUROLOGIC DISEASE; PATIENT COMPLIANCE; RANDOMIZED CONTROLLED TRIAL; RECURRENT DISEASE; RISK REDUCTION; SECONDARY PREVENTION; SIDE EFFECT; UREA NITROGEN BLOOD LEVEL;

AGED; CARDIOVASCULAR DISEASES; CORONARY DISEASE; DOUBLE-BLIND METHOD; DRUGS, CHINESE HERBAL; FEMALE; FOLLOW-UP STUDIES; HUMANS; HYPERTENSION; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; RISK FACTORS; TREATMENT OUTCOME;

EID: 70349292926     PISSN: 00912700     EISSN: 15524604     Source Type: Journal    
DOI: 10.1177/0091270009337509     Document Type: Article

References (24)

1. Turakhia M., Tseng ZH Sudden cardiac death: epidemiology, mechanisms, and therapy. Curr Probl Cardiol. 2007 ; 32: 501-546.
2. Hennekens CH Increasing burden of cardiovascular disease: current knowledge and future direction for research on risk factors. Circulation. 1998 ; 97: 1095-1102.
3. Casteli WP, Wilson PW, Levy D., et al. Cardiovascular risk factors in the elderly. Am J Cardiol. 1989 ; 63: 12H - 19H.
4. Njolstad I., Amesen E., Lund-Larsen PG Smoking, serum lipids, blood pressure, and sex differences in myocardial infarction: a 12-year follow-up of the Finnmark study. Circulation. 1996 ; 93: 450-456.
5. Sicard P., Zeller M., Dentan G., et al. Beneficial effects of statin therapy on survival in hypertensive patients with acute myocardial infarction: data from the RICO study. Am J Hypertens. 2007 ; 20: 1133-1139.
6. Kostis JB Treating hypertension in the very old. N Engl J Med. 2008 ; 358: 1958-1960.
7. He J., Gu D-F., Wu K-G., et al. Major causes of death among men and women in China. N Engl J Med. 2005 ; 353: 1124-1134.
8. Kronmal RA, Cain KC, Ye Z., et al. Total serum cholesterol levels and mortality risk as a function of age: a report based on the Framingham data. Arch Intern Med. 1993 ; 153: 1065-1073.
9. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive summary of the Third Report of the National Cholesterol Education Program (NCEP) (Adult Treatment Panel III). JAMA. 2001 ; 285: 2486-2497.
10. Nichols GA, Nag S., Chan W., et al. Intensity of lipid-lowering therapy and low-density lipoprotein cholesterol goal attainment among the elderly before and after the 2004 National Cholesterol Education Program Adult Treatment Panel III update. Am Heart J. 2007 ; 154: 554-560.
11. Baigent C., Keech A., Kearney PM, et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomized trials of statins. Lancet. 2005 ; 366: 1267-1278.
12. Lu Z-L., Kou W. -R, Du B-M., et al. Effects of Xuezhikang, an extract from red yeast Chinese rice, on coronary events in a Chinese population with previous myocardial infarction. Am J Cardiol. 2008 ; 101: 1689-1693.
13. Zhao S-P., Liu L., Cheng Y-C., et al. Xuezhikang, an extract of cholestin, protects endothelial function through anti-inflammatory and lipid-lowering mechanisms in patients with coronary heart disease. Circulation. 2004 ; 110: 915-920.
14. Li J-J., Hu S-S., Fang C-H., et al. Effects of Xuezhikang, an extract of cholestin, on lipid profile and C-reactive protein: a short-term time course study in patients with stable angina. Clin Chim Acta. 2005 ; 352: 217-224.
15. Li J-J., Wang Y., Nie S-P., et al. Xuezhikang, an extract of cholestin, decreases plasma inflammatory markers and endothelin-1, improve exercise-induced ischemia and subjective feeling in patients with cardiac syndrome X. Int J Cardiol. 2007 ; 122: 82-84.
16. Sever PS, Dahl?¶f B., Poulter NR, et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): a multicenter randomized controlled trial. Lancet. 2003 ; 361: 1149-1158. (Pubitemid 36398384)
17. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs usual care: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT-LLT). JAMA. 2002 ; 288: 2998-3007.
18. Hunt D., Young P., Simes J., et al. Benefits of pravastatin on cardiovascular events and mortality in older patients with coronary heart disease are equal to or exceed those seen in young patients: results from the LIPID trial. Ann Intern Med. 2001 ; 134: 931-940.
19. Miettinen TA, Pyorala K., Olsson AG, et al. Cholesterol-lowering therapy in women and elderly patients with myocardial infarction or angina pectoris: findings from the Scandianavian Simvastatin Survival Study (4S). Circulation. 1997 ; 96: 4211-4218.
20. Shepherd J., Blauw GJ, Murphy MB, et al. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomized controlled trial. Lancet. 2002 ; 360: 1623-1630.
21. Downs JR, Clearfield M., Weis S., et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA. 1998 ; 279: 1615-1661.
22. Stein EA, Illingworth DR, Kwiterovich PO Jr, et al. Efficacy and safety of lovastatin in adolescent males with heterozygous familial hypercholesterolemia: a randomized controlled trial. JAMA. 1999 ; 281: 180-181.
23. Nakamura H., Arakawa K., Itakura H., et al. Primary prevention of cardiovascular disease with pravastatin: in Japan (MEGA Study): a prospective randomized controlled trial. Lancet. 2006 ; 368: 1155-1163.
24. Lee E., Ryan S., Birmingham B., et al. Rosuvastatin pharmacokinetics and pharmacogenetics in white and Asian subjects residing in the same environment. Clin Pharmacol Ther. 2005 ; 78: 330-341.